Identification of Prognostic Markers of N6-Methylandenosine-Related Noncoding RNAs in Non-Small-Cell Lung Cancer

Figure 5

Efficacy evaluation of testing group: (a) KM survival analysis between high- and low-risk group, (b) area under ROC curve of 1, 2, and 3 years, (c) change of risk score over time, and (d) change of survival days and survival status over time.

(a)

(b)

(c)

(d)